Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization

Wu, Yu Wen; Lee, Deng-Yao; Lu, Yeh‐Lin; Delila, Liling; Nebie, Ouada; Barro, Lassina; Changou, Chun A.; Lu, Long‐Sheng; Goubran, Hadi; Burnouf, Thierry

doi:10.1080/09537104.2023.2237134

Cited by 9 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSC chemotherapeutic drug loading and delivery is an encouraging new area of advanced cell therapy for neoplastic diseases, especially for those with a poor prognosis and limited available treatment options [ 38 – 41 ]. Although some experimental models have been successfully developed [ 42 , 43 ], phase I clinical studies are needed to confirm this potential application of cell therapy [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

Stem cell technology for antitumor drug loading and delivery in oncology

PETRELLA,

CASSINA,

LIBRETTI

et al. 2024

View full text Add to dashboard Cite

The main aim of antineoplastic treatment is to maximize patient benefit by augmenting the drug accumulation within affected organs and tissues, thus incrementing drug effects and, at the same time, reducing the damage of noninvolved tissues to cytotoxic agents. Mesenchymal stromal cells (MSC) represent a group of undifferentiated multipotent cells presenting wide self-renewal features and the capacity to differentiate into an assortment of mesenchymal family cells. During the last year, they have been proposed as natural carriers for the selective release of antitumor drugs to malignant cells, thus optimizing cytotoxic action on cancer cells, while significantly reducing adverse side effects on healthy cells. MSC chemotherapeutic drug loading and delivery is an encouraging new area of cell therapy for several tumors, especially for those with unsatisfactory prognosis and limited treatment options available. Although some experimental models have been successfully developed, phase I clinical studies are needed to confirm this potential application of cell therapy, in particular in the case of primary and secondary lung cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Stem cell technology for antitumor drug loading and delivery in oncology

PETRELLA,

CASSINA,

LIBRETTI

et al. 2024

View full text Add to dashboard Cite

show abstract

“…A recent study also demonstrated that platelet-derived EVs, generated via extrusion, sonication or freeze/thaw, can be used as carriers of doxorubicin. Moreover, the administration of EVs packaged with doxorubicin potently induces anti-cancer effects in MDA-MB-231 breast cancer cells, and to a lesser extent in another breast cancer cell line, MCF7 [209].…”

Section: Potential Complications In Establishing Ev-based Therapeuticsmentioning

confidence: 99%

Extracellular Vesicles in Pathophysiology: A Prudent Target That Requires Careful Consideration

Shahi,

Kang,

Fonseka

2024

Cells

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are membrane-bound particles released by cells to perform multitudes of biological functions. Owing to their significant implications in diseases, the pathophysiological role of EVs continues to be extensively studied, leading research to neglect the need to explore their role in normal physiology. Despite this, many identified physiological functions of EVs, including, but not limited to, tissue repair, early development and aging, are attributed to their modulatory role in various signaling pathways via intercellular communication. EVs are widely perceived as a potential therapeutic strategy for better prognosis, primarily through utilization as a mode of delivery vehicle. Moreover, disease-associated EVs serve as candidates for the targeted inhibition by pharmacological or genetic means. However, these attempts are often accompanied by major challenges, such as off-target effects, which may result in adverse phenotypes. This renders the clinical efficacy of EVs elusive, indicating that further understanding of the specific role of EVs in physiology may enhance their utility. This review highlights the essential role of EVs in maintaining cellular homeostasis under different physiological settings, and also discusses the various aspects that may potentially hinder the robust utility of EV-based therapeutics.

show abstract

“…106 Contrary to previous findings, the phase III study showed no change in OS when treated with olaratumab + DOX. 103 Beyond traditional methods, there is also a growing interest in engineering cells, such as stem cells, macrophages, or RBCs, for drug delivery, 107,108 although concerns regarding safety and cost efficiency are noted in the literature. 109 As an alternative to doxorubicin, pegylated liposomal doxorubicin has been shown to be effective and has improved tolerability and a favorable toxicity profile as a single agent and in combination with ifosfamide.…”

Section: Cytotoxic Chemotherapiesmentioning

confidence: 99%

Emerging innovations and advancements in the treatment of extremity and truncal soft tissue sarcomas

Walker,

Simister,

Carr‐Ascher

et al. 2023

Journal of Surgical Oncology

View full text Add to dashboard Cite

In this special edition update on soft tissue sarcomas (STS), we cover classifications, emerging technologies, prognostic tools, radiation schemas, and treatment disparities in extremity and truncal STS. We discuss the importance of enhancing local control and reducing complications, including the role of innovative imaging, surgical guidance, and hypofractionated radiation. We review advancements in systemic and immunotherapeutic treatments and introduce disparities seen in this vulnerable population that must be considered to improve overall patient care.

show abstract

Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization

Cited by 9 publications

References 47 publications

Stem cell technology for antitumor drug loading and delivery in oncology

Stem cell technology for antitumor drug loading and delivery in oncology

Extracellular Vesicles in Pathophysiology: A Prudent Target That Requires Careful Consideration

Emerging innovations and advancements in the treatment of extremity and truncal soft tissue sarcomas

Contact Info

Product

Resources

About